nVector specializes in advanced biomarker testing services and gene therapy solutions aimed at treating central nervous system (CNS) diseases. Their proprietary GreenGlia Technology™ allows for targeted access to specific glial and neuronal cells, which is crucial for developing revolutionary treatments for conditions such as Alzheimer’s, Parkinson’s, and ALS. The nVector platform is designed to overcome existing barriers in gene therapy, such as limited gene expression and the challenge of targeting the right cells. With a library of 100 million novel adeno-associated virus (AAV) capsids, nVector provides customized solutions for various CNS gene therapy initiatives, enhancing the precision and efficacy of treatment delivery.

In addition to their gene therapy capabilities, nVector offers clinical diagnostic assays that significantly improve the diagnosis and prognosis of CNS diseases. Their innovative ALS diagnostic tests are not only cost-effective but also provide results much faster than traditional methods. nVector also engages in biomarker testing services for pharmaceutical and biotech companies, measuring protein biomarkers in human biofluids to support clinical trials. By developing customized assays for neurodegeneration and neuroinflammation, nVector aims to streamline the testing and trial development process, providing a competitive edge in the rapidly evolving field of CNS therapeutics.

United States

Leverage nVector's advanced Adeno-Associated Virus platform to quick-launch your gene therapy strategy or accelerate existing initiatives. We enhance testing and trials with superior diagnostic biomarkers.

nVector

Company Details